IM Cannabis Corp (IMCC) AI Stock Analysis

• Market Cap: $8.19M
• Dividend Yield: N/A
• Average Volume (3M): 72.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: -0.74%
• EPS Growth: 81.49%
• Country: US
• Employees: 95
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.54
• Shares Outstanding: 5,246,812
• 10 Day Avg. Volume: 74,089
• 30 Day Avg. Volume: 72,265
• PEG Ratio: -0.55
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 0.15
• P/FCF Ratio: -6.38
• Enterprise Value/Market Cap: 3.59
• Enterprise Value/Revenue: 0.56
• Enterprise Value/Gross Profit: 2.39
• Enterprise Value/Ebitda: -13.53
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.00 ▲(28.21% Upside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by ongoing losses and negative cash flows. Technical analysis provides a slightly positive outlook due to short-term momentum, but valuation concerns due to a negative P/E ratio and lack of dividends weigh heavily. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

New CFO Appointment

The appointment of a new CFO with extensive experience may enhance financial management and operational efficiency, supporting strategic goals.

Strategic Partnerships

Strategic partnerships can expand market reach and product offerings, contributing to long-term revenue growth and competitive positioning.

Focus on Quality and Compliance

Commitment to quality and compliance can build trust with customers and regulators, ensuring sustainable operations and market access.

Negative Factors

Negative Cash Flows

Persistent negative cash flows indicate insufficient internal cash generation, potentially pressuring liquidity and limiting growth investments.

Rising Debt Levels

Increased reliance on debt can limit financial flexibility and increase financial risk, impacting long-term stability and shareholder value.

Declining Revenue Growth

Inconsistent revenue growth suggests challenges in market competitiveness or demand, potentially impacting long-term profitability and market position.

IM Cannabis Corp Business Overview & Revenue Model

Company Description

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.

How the Company Makes Money

IM Cannabis Corp generates revenue primarily through the sale of medical cannabis products to patients and healthcare providers. The company's revenue model is built on the cultivation and processing of cannabis, which is then marketed and sold through its proprietary retail outlets and online platforms. Key revenue streams include direct sales of cannabis products, as well as wholesale distribution to licensed dispensaries. Additionally, IMCC has engaged in strategic partnerships and collaborations that enhance its market reach and product offerings, contributing to its overall earnings. The company's focus on quality and compliance with regulatory standards further strengthens its position in the competitive cannabis market.

IM Cannabis Corp Financial Statement Overview

Summary

IM Cannabis Corp faces significant financial challenges with ongoing losses, rising leverage, and negative cash flows. The company needs to address its cost structure and improve revenue generation to stabilize its financial position. Current trends reflect potential risks in sustaining operations without strategic changes or external financing.

Income Statement

The company has been struggling with profitability, demonstrated by consistent negative net income and declining gross profit margins. The net profit margin is significantly negative, indicating challenges in controlling costs and generating sustainable profits. Revenue growth is inconsistent, with recent declines, suggesting potential issues in market competitiveness or demand.

Balance Sheet

The debt-to-equity ratio has increased, reflecting a higher reliance on debt financing, which could limit financial flexibility. The return on equity is negative due to losses, which is concerning for long-term shareholder value. The equity ratio has decreased, indicating a lower proportion of equity financing, which might increase financial risk.

Cash Flow

The company has been experiencing negative operating and free cash flows, although there is some improvement in the operating cash flow to net income ratio. However, free cash flow remains negative, suggesting insufficient internal cash generation to cover capital needs, which could pressure liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.38M	54.03M	48.80M	54.34M	34.05M	15.89M
Gross Profit	12.28M	8.45M	9.85M	9.16M	6.33M	10.47M
EBITDA	-2.17M	-6.14M	-2.79M	-16.76M	6.24M	-7.04M
Net Income	-4.70M	-10.59M	-9.50M	-188.89M	-17.76M	-28.70M
Balance Sheet
Total Assets	44.33M	39.19M	48.81M	60.68M	287.39M	38.12M
Cash, Cash Equivalents and Short-Term Investments	1.18M	863.00K	1.81M	2.45M	13.90M	8.88M
Total Debt	17.56M	18.01M	13.78M	11.53M	29.27M	990.00K
Total Liabilities	40.03M	36.04M	35.11M	36.88M	82.44M	25.51M
Stockholders Equity	3.96M	5.24M	14.47M	22.65M	201.24M	11.10M
Cash Flow
Free Cash Flow	-3.75M	-1.23M	-8.66M	-14.20M	-38.97M	-10.63M
Operating Cash Flow	-3.71M	-1.08M	-8.07M	-12.64M	-34.37M	-7.92M
Investing Cash Flow	-1.08M	-470.00K	-1.18M	-1.41M	-9.01M	-4.08M
Financing Cash Flow	7.12M	3.83M	9.42M	4.76M	48.73M	6.74M

IM Cannabis Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMCC, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.66, below the 50-day MA of 1.59, and below the 200-day MA of 2.07, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.90 is Neutral, neither overbought nor oversold. The STOCH value of 32.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMCC.

IM Cannabis Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMCC	45 Neutral	$8.19M	-1.99	-93.87%	―	-0.74%	81.49%
CANB	44 Neutral	C$3.46M	-4.17	-11.42%	―	-5.87%	-239.53%
CDVA	41 Neutral	C$3.84M	-1.33	―	―	1.60%	-213.10%
PCLO	24 Underperform	C$6.92M	-1.26	―	―	15.64%	58.47%

IM Cannabis Corp Corporate Events

IM Cannabis Corp. Appoints New CFO Asi Levi

On December 11, 2025, IM Cannabis Corp. announced the appointment of Asi Levi as the new Chief Financial Officer, effective immediately, succeeding Uri Birenberg who resigned for personal reasons. Mr. Levi brings over 15 years of experience in finance and controlling roles, having worked with various companies in similar capacities. This leadership change is expected to support IM Cannabis Corp.’s strategic goals in its key markets of Israel and Germany, potentially enhancing its financial management and operational efficiency.

IM Cannabis Corp. Cancels December 2025 Special Meeting

IM Cannabis Corp. announced the cancellation of a Special Meeting of Security Holders that was initially scheduled for December 29, 2025. The cancellation notice, dated November 14, 2025, affects various record dates related to the meeting, including the notice of meeting, voting, and beneficial ownership determination, all of which were set for November 12, 2025. This cancellation may impact stakeholders’ expectations and the company’s planned corporate actions.

IM Cannabis Corp. to Announce Q3 2025 Financial Results

On November 6, 2025, IM Cannabis Corp. announced it will report its third quarter 2025 financial results on November 13, 2025. The company, which operates in Israel and Germany, aims to provide insights into its operational and financial performance for the quarter ended September 30, 2025. This announcement is significant as it reflects the company’s ongoing commitment to transparency and its strategic focus on growth in high-value markets, potentially impacting its market positioning and stakeholder interests.

IM Cannabis Corp. Announces CFO Departure Amid Transition Plans

On October 29, 2025, IM Cannabis Corp. announced that its Chief Financial Officer, Uri Birenberg, will be stepping down for personal reasons. He will continue in his role until January 5, 2026, or an earlier date determined by the company, assisting in a structured transition process. This change is not due to any disagreement with the company, and Birenberg expressed confidence in IM Cannabis’s future. The company is actively searching for a new CFO, which may impact its operations and stakeholder confidence during the transition.

IM Cannabis Corp. Announces Special Meeting for December 2025

IM Cannabis Corp. has announced a Special Meeting of Security Holders scheduled for December 29, 2025, in Toronto, Ontario. The meeting’s record date for notice and voting is set for November 12, 2025. This meeting is significant for stakeholders as it may influence the company’s strategic decisions and future direction, impacting its market positioning and operational strategies.

IM Cannabis Corp. Announces Board Restructuring and Strategic Expansion Plans

On September 15, 2025, IM Cannabis Corp. announced significant changes to its Board of Directors, with the resignation of Shmulik Arbel and Brian Schinderle, and the appointment of Asaf Yitzhaik and Eli Zamir as their replacements. The company also appointed Oz Adler as the new Chairman of the Board. These changes are part of a strategic review aimed at exploring additional business opportunities to enhance long-term growth and shareholder value.